FDA Proposes Guidelines to Decrease Animal Testing in Cancer Drug Development

The U.S. FDA has published draft guidance aimed at minimizing animal testing during the nonclinical safety assessment of certain cancer drugs. The recommendations suggest eliminating redundant animal studies, utilizing a single relevant species, or substituting animal tests with alternative evidence-based methods. This initiative aligns with the FDA's goal to accelerate new treatment approvals and reduce animal use in research.